EKF Diagnostics Holdings PLC
LSE:EKF
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EKF Diagnostics Holdings PLC
Cash & Cash Equivalents
EKF Diagnostics Holdings PLC
Cash & Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
EKF Diagnostics Holdings PLC
LSE:EKF
|
Cash & Cash Equivalents
£15.8m
|
CAGR 3-Years
11%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
23%
|
|
|
Smith & Nephew PLC
LSE:SN
|
Cash & Cash Equivalents
$557m
|
CAGR 3-Years
17%
|
CAGR 5-Years
-21%
|
CAGR 10-Years
N/A
|
|
|
LivaNova PLC
NASDAQ:LIVN
|
Cash & Cash Equivalents
$635.6m
|
CAGR 3-Years
44%
|
CAGR 5-Years
20%
|
CAGR 10-Years
19%
|
|
|
Creo Medical Group PLC
LSE:CREO
|
Cash & Cash Equivalents
£8.7m
|
CAGR 3-Years
-42%
|
CAGR 5-Years
-36%
|
CAGR 10-Years
N/A
|
|
|
Inspiration Healthcare Group PLC
LSE:IHC
|
Cash & Cash Equivalents
£620k
|
CAGR 3-Years
-41%
|
CAGR 5-Years
-40%
|
CAGR 10-Years
-11%
|
|
|
EMV Capital PLC
LSE:EMVC
|
Cash & Cash Equivalents
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
EKF Diagnostics Holdings PLC
Glance View
EKF Diagnostics Holdings Plc is a vitro diagnostics company, which designs and manufactures diagnostic equipment for use within point-of-care settings. The company is headquartered in Penarth, South Glamorgan. The company went IPO on 2002-06-05. The firm's point-of-care range includes hemoglobin analyzers, HbA1c analyzers and glucose analyzers for use in the screening, monitoring and diagnosis of patients, as well as rapid tests for pregnancy and common infectious diseases. Its Central Laboratory division includes a range of products for use in both large and small laboratory facilities. Its subsidiary, EKF Life Sciences, provides bulk diagnostic enzyme manufacturing and fermentation services. EKF Life Sciences specializes in producing enzymes, including Salicylate Hydroxylase and Beta-Hydroxybutyrate Dehydrogenase. Its products include Quo-Test A1c, Biosen, Quo-Lab A1c, UltraCrit, DiaSpect, HemataStat II and Creamatocrit Plus. The company operates in Germany, the United States, Russia and the United Kingdom.
See Also
What is EKF Diagnostics Holdings PLC's Cash & Cash Equivalents?
Cash & Cash Equivalents
15.8m
GBP
Based on the financial report for Dec 31, 2025, EKF Diagnostics Holdings PLC's Cash & Cash Equivalents amounts to 15.8m GBP.
What is EKF Diagnostics Holdings PLC's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 10Y
23%
Over the last year, the Cash & Cash Equivalents growth was 11%. The average annual Cash & Cash Equivalents growth rates for EKF Diagnostics Holdings PLC have been 11% over the past three years , -6% over the past five years , and 23% over the past ten years .
